We begin this week with news from Patheon who has announced that Antonella Mancuso, President Global Commercial Operations and Chief Manufacturing Officer plans to resign from her positions with the company and its subsidiaries, effective July 10.
Mancuso, who was appointed to the role in January 2012, has been with Patheon for over twelve years, beginning as Production Manager of Patheon's facility in Monza, Italy.
And read about the recent shuttering of one of Patheon’s manufacturing sites in the wake of the acquisition of Banner Pharmacaps here.
Dr. Sumant Ramachandra has been reappointed to his role as senior vice president and chief scientific officer, resuming responsibility for Hospira's global R&D, regulatory and medical affairs organization.
Ramachandra returns after departing briefly earlier this year and CEO F. Michael Ball said he was “thrilled to welcome Sumant back to the Hospira team. While we had interviewed an exceptional slate of candidates for this role, we determined that Sumant remained not only the best fit, but also would be best positioned to seamlessly advance our R&D priorities.”
In other Hospira news, the company in its 2013 Shareholders Meeting has appointed four new Directors: Dr. Connie Curran; William Dempsey; Dennis Fenton; Heino von Prondzynski; and Dr. Mark Wheeler.
Next to the UK and SCM Pharma has announced it has appointed Paul Bradley as its new Director.
Bradley has over 15 years of experience of research, development and manufacturing and he will now be responsible for all operational activities at SCM Pharma including production, warehouse and facilities.
Managing Director Dianne Sharp said: “We are delighted to have Paul join the team as he brings a very distinct and important set of skills relating to operations to the management team.”
And read here about the supply contract SCM won this month for BTG’s candidate treatment, Varisolve.
Next we go to Celerion who has appointed Dr. Bruce Morimoto as Executive Director of Applied Translational Medicine.
Morimoto comes to Celerion with over 20 years of experience in the industry, his last role being Vice President of Drug Development at Allon Therapeutics, and will have responsibility for developing and implementing strategies for patient populations in early clinical research and clinical pharmacology studies.
According to company CEO, Susan Thornton: “His in-depth knowledge of drug development as well as focus on Applied Translational Medicine from both the client and CRO perspective will be a great asset to our organization.”
And read about Celerion’s full accreditation from theAAHRPP here.
To Israel now and Biotec Services has expanded its presence by appointing Dr. Kela-Madar to strengthen its Business Development Team, using her broad network in the Israeli and US Biotechnology industries.
“I am very happy to be joining an International organisation like Biotec who has a fantastic reputation in the industry and I look forward to being part of its future success,” said Dr. Kela-Madar.
“I fully intend to make an immediate contribution to the success of the territories for which I am responsible, to create new collaborations and to promote Biotec's range of services.”
And finally this week we have news from CRO vivoPharm who has appointed a new Director in the guise of John Lambrick - the General Counsel of RMIT University, based in Melbourne, Australia.